ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome ... ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Show more
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.56 | -12 | 13 | 13.62 | 11.47 | 455765 | 12.69329215 | CS |
4 | -7.52 | -39.6624472574 | 18.96 | 21.315 | 11.47 | 323453 | 15.13985668 | CS |
12 | -16.12 | -58.4905660377 | 27.56 | 28.25 | 11.47 | 306800 | 19.81094894 | CS |
26 | -14.06 | -55.137254902 | 25.5 | 31.13 | 11.47 | 204284 | 21.07868285 | CS |
52 | -14.06 | -55.137254902 | 25.5 | 31.13 | 11.47 | 204284 | 21.07868285 | CS |
156 | -14.06 | -55.137254902 | 25.5 | 31.13 | 11.47 | 204284 | 21.07868285 | CS |
260 | -14.06 | -55.137254902 | 25.5 | 31.13 | 11.47 | 204284 | 21.07868285 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales